Exercise during adjuvant treatment for colorectal cancer: treatment completion, treatment-related toxicities, body composition, and serum level of adipokines

References

• Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Prev Biomarkers. 2010;19(8):1055–9965. EPI–1010–0437.
   Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–358. doi:10.1056/NEJM1990020832206022300087
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116. doi:10.1200/JCO.2008.20.677119451431
   PubMed Web of Science ®Google Scholar
• Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28(2):264. doi:10.1200/JCO.2009.24.095219949014
   PubMed Web of Science ®Google Scholar
• Morris M, Platell C, Fritschi L, Iacopetta B. Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer. 2007;96(5):701. doi:10.1038/sj.bjc.660362717299387
   PubMed Web of Science ®Google Scholar
• André T, Iveson T, Labianca R, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: trial design and current status. Curr Colorectal Cancer Rep. 2013;9(3):261–269.24032000
   PubMedGoogle Scholar
• André T, Vernerey D, Mineur L, et al. Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage iii colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. J Clin Oncol. 2018;36(15):1469–1477. doi:10.1200/JCO.2017.76.035529620995
   PubMed Web of Science ®Google Scholar
• Dobie SA, Baldwin L-M, Dominitz JA, Matthews B, Billingsley K, Barlow W. Completion of therapy by medicare patients with stage III colon cancer. JNCI. 2006;98(9):610–619. doi:10.1093/jnci/djj15916670386
   PubMedGoogle Scholar
• Berger AM, Grem JL, Visovsky C, Marunda HA, Yurkovich JM. Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer. Oncol Nurs Forum 2010;37(6):E359–69. doi:10.1188/10.ONF.E359-E369.
   Google Scholar
• Puetz TW, Herring M. Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis. Am J Prev Med. 2012;43(2):e1–e24.22813691
   PubMed Web of Science ®Google Scholar
• Van JV, Velthuis MJ, Steins CB, et al. Effects of an exercise program in colon cancer patients undergoing chemotherapy. Med Sci Sports Exerc. 2016;48(5):767–775.26694846
   PubMed Web of Science ®Google Scholar
• Dawes HN, Barker KL, Cockburn J, et al. Borg’s rating of perceived exertion scales: do the verbal anchors mean the same for different clinical groups? Arch Phys Med Rehabil. 2005;86(5):912–916.15895336
   PubMed Web of Science ®Google Scholar
• Irlbeck T, Massaro J, Bamberg F, O’Donnell C, Hoffmann U, Fox C. Association between single-slice measurements of visceral and abdominal subcutaneous adipose tissue with volumetric measurements: the Framingham Heart Study. Int J Obes. 2010;34(4):781–787. doi:10.1038/ijo.2009.279
   Web of Science ®Google Scholar
• De Backer IC, Van Breda E, Vreugdenhil A, Nijziel MR, Kester AD, Schep GJAO. High-intensity strength training improves quality of life in cancer survivors. Acta Oncol. 2007;46(8):1143–1151.17851864
   PubMed Web of Science ®Google Scholar
• Shariati A, Haghighi S, Fayyazi S, Tabesh H, Kalboland MMJIjon, research m. The effect of exercise on the severity of the fatigue in colorectal cancer patients who received chemotherapy in Ahwaz. Iran J Nurs Midwifery Res. 2010;15(4):145.21589787
   PubMedGoogle Scholar
• Jeon J, Sato K, Niedzwiecki D, et al. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: findings from CALGB 89803/Alliance. Clin Colorectal Cancer. 2013;12(4):233–238.24035029
   PubMed Web of Science ®Google Scholar
• Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002;50(5):889–896.12028177
   PubMed Web of Science ®Google Scholar
• Pichard C, Kyle UG, Morabia A, Perrier A, Vermeulen B, Unger P. Nutritional assessment: lean body mass depletion at hospital admission is associated with an increased length of stay. Am J Clin Nutr 2004;79(4):613–618.15051605
   PubMed Web of Science ®Google Scholar
• Cosquéric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-Engerer S. Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr. 2006;96(5):895–901.17092379
   PubMed Web of Science ®Google Scholar
• Awad S, Tan BH, Cui H, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr. 2012;31(1):74–77.21875767
   PubMed Web of Science ®Google Scholar
• Palle SS, Møllehave LT, Taheri-Kadkhoda Z, et al. Multi-frequency bioelectrical impedance analysis (BIA) compared to magnetic resonance imaging (MRI) for estimation of fat-free mass in colorectal cancer patients treated with chemotherapy. Clin Nutr ESPEN. 2016;16:8–15.28531456
   PubMedGoogle Scholar
• Baracos V, Caserotti P, Earthman CP, et al. Advances in the science and application of body composition measurement. JPEN J Parenter Enteral Nutr 2012;36(1):96–107.22235108
   PubMed Web of Science ®Google Scholar
• Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. PROTEOMICS–Clin Appl. 2012;6(1‐2):91–101.22213627
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772. doi:10.1038/nri193716998510
   PubMed Web of Science ®Google Scholar
• Konturek P, Brzozowski T, Sulekova Z, Meixner H, Hahn E, Konturek S. Enhanced expression of leptin following acute gastric injury in rat. J Physiol Pharmacol. 1999;50(4):587–595.10639009
   PubMed Web of Science ®Google Scholar
• Aloulou N, Bastuji-Garin S, Le Gouvello S, et al. Involvement of the leptin receptor in the immune response in intestinal cancer. Cancer Res. 2008;68(22):9413–9422. doi:10.1158/0008-5472.CAN-08-090919010916
   PubMed Web of Science ®Google Scholar
• Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148(3):293–300. doi:10.1530/eje.0.148029312611609
   PubMed Web of Science ®Google Scholar
• Sugiyama M, Takahashi H, Hosono K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol. 2009;34(2):339–344.19148467
   PubMed Web of Science ®Google Scholar
• Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res. 2010;70(13):0008–5472. CAN–0010–0178.
   PubMed Web of Science ®Google Scholar
• Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149–1160. doi:10.3758/BRM.41.3.69119897823
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical Power Analysis for the Behaviors Science. 2nd ed. New Jersey: Laurence Erlbaum Associates, Publishers, Hillsdale; 1988.
   Google Scholar